5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex

Expert Opinion on Therapeutic Targets · Published 2026-07-03 · DOI 10.1080/14728222.2026.2706483

Authors (10)

Subarno Paul, Chinmay Das, Subhasmita Bhal, Saptarshi Sinha, Somya Ranjan Dash, Sushree Subhadra Acharya, Aakash Goswami, Kunal Goutam, Chanakya Nath Kundu, Tithi Parija

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Paul, S., Das, C., Bhal, S., et al. (2026). 5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2026.2706483

Related articles

• Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illness · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Molecular targets in gastric cancer for nanomedicine therapeutics: mechanistic insights and translational progress · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• AQP7 suppresses cell stemness and metastasis by targeting Wnt signaling in basal-like breast cancer · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later? · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Unveiling the role of mineralocorticoid receptor antagonists in epilepsy: the intersection of seizures, stress, and neuroinflammation · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• An overview of outer membrane protein A (OmpA) as a therapeutic target for Acinetobacter baumannii infection · Expert Opinion on Therapeutic Targets · 2026 · Same journal